Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.

Always stay updated with the free CMN Newsletter.

Tome Bioscience Inc.

Company Type: Therapeutic development

Main focus: New treatments for patients via the development of novel cell and integrative gene therapies

Company stage: Pre-clinical

Diseases: Monogenic liver diseases and autoimmune diseases

Genome-editing tool: Programmable Genomic Integration (PGI), using CRISPR-Cas9

Funding stage: Series A

Location: Watertown, Massachusetts, USA

Website: https://tome.bio/

Pipeline:

Partners:

Tome Biosciences, Inc. is the developer of the programmable genomic integration (PGI) technology that allows for site-specific insertion of genetic sequences of any size into the genome. PGI combines the site-specificity of CRISPR/Cas9 with enzymes capable of inserting sequences without the need for double-strand DNA breaks. The company plans to develop integrative gene therapies for monogenic liver diseases and cell therapies for autoimmune diseases.

Tome Biosciences

Press Releases

Related News and Updates

Job Opportunities

Clinical Trials

Pre-clinical Trials

Stocks and Markets

Diseases

Webinar

Your Latest CMN News

CMN Weekly (21 February 2025) - Your Weekly CRISPR...

CMN Weekly

Feb. 21, 2025

Some of the best links we picked up around the internet

Bahrain Reports First Administration of CASGEVY in...

Feb. 19, 2025

The Bahrain Oncology Centre announced a major milestone on Sunday with the successful administration of CASGEVY - the world's only approved therapy...

CRISPR–Csm enables single-molecule RNA imaging in...

CMN Briefs

Feb. 18, 2025

A new technique developed by Jennifer Doudna and colleagues at the University of California, Berkeley, achieves single-molecule resolution imaging of...

CRISPR screen links BAF mutation to premature...

CMN Briefs

Feb. 17, 2025

A genome-wide CRISPR screen in fibroblasts from patients with Néstor-Guillermo Progeria Syndrome (NGPS) identified 43 genes that mitigate multiple...

CMN Weekly (14 February 2025) - Your Weekly CRISPR...

CMN Weekly

Feb. 14, 2025

Some of the best links we picked up around the internet

FDA Grants Dual Designations to Arbor's Gene...

CMN Clinical

Feb. 12, 2025

The FDA has granted orphan drug and rare pediatric disease designations to Arbor Biotechnologies' ABO-101, a gene-editing therapeutic candidate for...